Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

• Published in: Journal of the American Academy of Dermatology Vol. 73; no. 3; pp. 400 - 409
• Main Authors: Thaçi, Diamant, Blauvelt, Andrew, Reich, Kristian, Tsai, Tsen-Fang, Vanaclocha, Francisco, Kingo, Külli, Ziv, Michael, Pinter, Andreas, Hugot, Sophie, You, Ruquan, Milutinovic, Marina
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2015
• Subjects: 90% or more improvement in baseline Psoriasis Area and Severity Index; Adult; Analysis of Variance; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; clear or almost clear skin; clinical trial; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; head to head; Humans; Injections, Subcutaneous; Male; Maximum Tolerated Dose; Middle Aged; plaque psoriasis; Psoriasis - diagnosis; Psoriasis - drug therapy; Reference Values; Risk Assessment; secukinumab; Severity of Illness Index; superiority; Treatment Outcome; ustekinumab; Ustekinumab - administration & dosage; Ustekinumab - adverse effects; clinical trial; DLQI; PASI 90; IGA; PASI; IL; superiority; AE; IGA mod 2011; MedDRA; secukinumab; PASI 75; clear or almost clear skin; TNF; head to head; PASI 100; ustekinumab; SAE; plaque psoriasis; HRQoL; 90% or more improvement in baseline Psoriasis Area and Severity Index; investigator global assessment 2011 modified version; Psoriasis Area and Severity Index; Medical Dictionary for Regulatory Activities; serious adverse event; 75% or more improvement from baseline Psoriasis Area and Severity Index score; interleukin; 100% improvement from baseline Psoriasis Area and Severity Index score; adverse event; health-related quality of life; 90% or more improvement from baseline Psoriasis Area and Severity Index score; investigator global assessment; tumor necrosis factor; Dermatology Life Quality Index

Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has shown superior efficacy to etanercept with similar safety in moderate to severe plaque psoriasis (FIXTURE study). We sought to directly compare efficacy and safety of secukinumab versus ustekinumab. In this 52-week, double-blin...